Your selection
Innovation, Patient care / 13.08.2024
Eckert & Ziegler becomes European contract manufacturer for Telix's innovative Phase III ProstACT GLOBAL study
Eckert & Ziegler and Telix Pharmaceuticals Limited (Telix) today announced the signing of a significant multi-year agreement under which Eckert & Ziegler will serve as the European contract manufacturing organization (CMO) for Telix's ProstACT GLOBAL Phase III study. The contract covers the supply of the entire European patient base from the state-of-the-art facility in Berlin. In addition, Eckert & Ziegler will also be a provider of the crucial starting material in the form of their high-purity, non-carrier added GMP-grade Lutetium-177 (Lu-177).
Telix's ProstACT GLOBAL study is investigating the benefits and risks of Lutetium (Lu 177) rosopatamab tetraxetan, a radio-labeled antibody drug conjugate (rADC), in adult males with prostate-specific membrane antigen (PSMA) positive prostate cancer in combination with standard of care.
"We are happy to further expand our long-standing and successful collaboration with Telix," said Dr. Harald Hasselmann, CEO of Eckert & Ziegler SE. "This contract underlines not only the importance of our leading-edge facility in Berlin, but also our role as an integral service provider in the continuously growing radiopharmaceutical market."
Darren Patti, Group Chief Operating Officer of Telix, added: "The decision to work with Eckert & Ziegler is based on their outstanding expertise and the quality of their facilities. We are convinced that this continued strategic partnership will contribute significantly to the success of our ProstACT GLOBAL study."
The collaboration marks an important step in both companies' ongoing efforts to advance innovative solutions in the field of radiopharmaceuticals. Eckert & Ziegler operates several CMO sites worldwide and offers a range of other services along the entire value chain.
Source: Press Release Eckert & Ziegler
Eckert & Ziegler becomes European contract manufacturer for Telix's innovative Phase III ProstACT GLOBAL study
Overview News
News Buch Berlin
Eckert & Ziegler and GlyTherix Sign Agreement for Lutetium-177 Supply
Eckert & Ziegler (ISIN DE0005659700, SDAX) and GlyTherix Ltd (GlyTherix), an Australian targeted radiotherapy company specialising in developing antibody radiopharmaceuticals for solid tumors, today a...
more ...Eckert & Ziegler: Spin-off of Pentixapharm AG Registered with the Commercial Register
Eckert & Ziegler SE (ISIN DE0005659700, TecDAX) announces that the spin-off resolution approved at the Annual General Meeting on 26 June 2024 was entered in the commercial register of the Charlottenbu...
more ...OMEICOS Completes Enrollment of PMD-OPTION Study in Primary Mitochondrial Disease
Interim data confirms OMT-28's strong safety profile in PMD patients, top-line data expected mid-2025
more ...Events Buch Berlin
24.10.2024, 17:00
Autorenlesung: "Sofia Tolstaja: Die Frau an der Seite Leo Tolstojs"
Natalja Sharandak gibt anhand von Tolstois Tagebüchern und Briefen Einblicke in das Leben von Sofia und Lew Tolstoi und zeigt sie als kluge, sozial engagierte und literarisch begabte Frau. Die Lesung ...
more ...25.10.2024, 20:00
Scheunen-Party Ü40
Scheunen-Party in der Feste Scheune
more ...26.10.2024, 13:30
Naturwanderung Bogensee - Geschichte und Pflanzenwelt
Der Historiker und Naturfreund Stefan Hückler aus Karow zeigt bei einer Wanderung durch das Bucher Bogenseeareal die Vielfalt und Schönheit dieser kleinen Seenkette. Bereits in der Bronzezeit wurde di...
more ...
